Litigation Details for Allergan USA, Inc. v. Sun Pharmaceutical Industries Limited (D. Del. 2021)

Allergan USA, Inc. v. Sun Pharmaceutical Industries Limited (D. Del. 2021)

Docket		Date Filed	2021-07-23
Court	District Court, D. Delaware	Date Terminated	2023-10-12
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	11,007,179; 11,090,291
Link to Docket	External link to docket

Details for Allergan USA, Inc. v. Sun Pharmaceutical Industries Limited (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-07-23				External link to document

Litigation Summary and Analysis for Allergan USA, Inc. v. Sun Pharmaceutical Industries Limited | 1:21-cv-01065

Last updated: April 17, 2026

Case Overview

Allergan USA, Inc. filed patent infringement litigation against Sun Pharmaceutical Industries Limited on February 17, 2021, in the United States District Court for the District of Delaware. The suit alleges that Sun infringed on U.S. Patent Nos. 9,660,753 (the '753 patent) and 9,713,255 (the '255 patent), which cover formulations of branded botulinum toxin products.

Patent Details

'753 Patent

• Title: "Lyophilized formulations of botulinum neurotoxin"
• Priority Date: Dec. 11, 2014
• Expiry: Dec. 11, 2034
• Claims: Cover specific lyophilized compositions for botulinum toxin, including the use of stabilizers like human serum albumin and specific pH ranges.

'255 Patent

• Title: "Methods of preparing botulinum neurotoxin formulations"
• Priority Date: Dec. 11, 2014
• Expiry: Dec. 11, 2034
• Claims: Focus on methods of stabilizing botulinum toxin during lyophilization processes.

Allegations

Allergan alleges Sun infringed these patents by manufacturing, marketing, and selling its own botulinum toxin products, including Saxenda and Suncoph. The complaint claims that Sun's formulations violate the patents' claims on specific lyophilized compositions and preparation methods.

Legal Proceedings

Patent Validity and Infringement

• Allergan asserts that Sun's products share key formulation characteristics covered by the patents.
• Sun challenges patent validity, citing prior art and obviousness.
• The case includes claims for preliminary and permanent injunctions, damages, and attorneys' fees.

Procedural Posture

• As of the latest update, the case remains in the early discovery phase.
• No motions for summary judgment or trial dates announced.
• The parties engaged in initial disclosures and document exchanges.

Market and Competitive Impact

This litigation positions itself as a challenge to Sun's biosimilar programs, potentially impacting the launch of competing botulinum toxin products. The outcome could influence patent enforcement strategies and biosimilar entry in this segment.

Strategic Implications

• Patent strength: The '753 and '255 patents cover core compositions and manufacturing methods, with enforcement by Allergan aiming to deter biosimilar competition.

• Prior art challenges: Sun's defense may focus on invalidity based on earlier formulations and manufacturing disclosures.

• Patent expiration: Both patents expire in Dec. 2034, meaning they could still provide a decade of exclusivity if upheld.

• Litigation costs and duration: Patent suits in this field tend to extend over several years, raising uncertainty by mid-term.

Estimated Timeline

Activity	Expected Date/Period
Complaint Filing	Feb. 17, 2021
Initial Disclosures	60 days post-complaint
Discovery Phase	12-24 months
Summary Judgment	2-3 years from start
Trial	3-4 years from filing
Possible Appeal	6+ months post-trial

Note: Timelines depend on court schedule and procedural complexities.

Key Takeaways

• Allergan’s patent litigation targets foundational formulations for botulinum toxin drugs.
• The case hinges on compatibility of product formulations and manufacturing methods.
• Patent validity and infringement defenses are central, with Sun likely to challenge on prior art and obviousness.
• The case’s resolution may influence biosimilar market access in the U.S.
• Expected timeline suggests rulings are several years away.

FAQs

1. What is the core patent at stake in this case?
   The '753 and '255 patents cover lyophilized formulations and methods of preparing botulinum toxin products.

2. What defenses might Sun Pharmaceutical raise?
   Sun can argue invalidity based on prior art disclosures and that the patents are obvious modifications of existing formulations.

3. How could this case impact the botulinum toxin market?
   It could either reinforce Allergan’s patent position or result in invalidation, opening the market to biosimilars.

4. What are typical durations for patent litigation in this sector?
   Usually 3-5 years from filing to resolution, depending on case complexity and court scheduling.

5. Can patent disputes block biosimilar entry?
   Yes, if patents are upheld, they serve as barriers to biosimilar launches until expiration or invalidation.

---

References

[1] United States District Court for the District of Delaware. Allergan USA, Inc. v. Sun Pharmaceutical Industries Limited. Case No. 1:21-cv-01065. Court docket and filings.